ALLO
Allogene Therapeutics
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Allogene Therapeutics receives FDA RMAT designation for Cema-Cel as first-line consolidation therapy in large B-cell lymphomaJul 29, 2026
- Allogene Therapeutics published Phase 1 results for ALLO-316 showing durable remissions in metastatic solid tumorsJul 15, 2026
- Allogene Therapeutics expanded its pivotal Phase 2 ALPHA3 trial into South Korea and AustraliaApr 21, 2026
- Allogene reported interim data from ALPHA3 trial showing higher MRD clearance with Cema-CelApr 13, 2026
- Natera highlighted positive interim futility analysis from Allogene’s ALPHA3 trial in lymphomaApr 13, 2026